2025
Pericardial Disease: Contemporary Techniques and Management
Bae J, Saleh A, Hu J, Setaro J, Altin S. Pericardial Disease: Contemporary Techniques and Management. Current Treatment Options In Cardiovascular Medicine 2025, 27: 23. DOI: 10.1007/s11936-025-01081-7.Peer-Reviewed Original ResearchTreatment of recurrent pericarditisManagement of pericardial diseasesImmunosuppressive therapyRecurrent pericarditisTransthoracic echocardiographySignificant management challengeRefractory casesRecurrence ratePericardial diseaseTherapeutic optionsPharmacological therapyTherapeutic advancesClinical trialsTherapeutic approachesPoor visualizationDiagnostic precisionTherapyPatientsDiseaseDiagnostic techniquesSymptom burdenEvidence-basedPatient careTransthoracicEchocardiographyColorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects
Gonzalez R, Horton R, Zhang X, Graham R, Longacre T, Mehrotra A, Allende D, McHugh K, Shia J, Westerhoff M, Srivastava A, Chen W, Vazzano J, Swanson P, Chatterjee D, Cheema H, Ma C, Mannan R, Chetty R, Nowak K, Serra S, Agostini‐Vulaj D, Kazemimood R, Henn P, Kakar S, Choi W, Adeyi O, Jenkins S, Nagtegaal I. Colorectal adenosquamous carcinoma: clinicopathologic analysis of two large cohorts and literature review confirm poor prognosis and reveal prognostic aspects. Histopathology 2025 PMID: 39887413, DOI: 10.1111/his.15412.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesAdenosquamous carcinomaColorectal adenosquamous carcinomaTumor buddingPoor prognosisMedian time to progressionMeta-analysis of cohortLow tumor buddingTime to progressionMale:female ratioReview of casesIndividual case seriesNodal metastasisRecurrent diseaseSquamous componentPatient ageRecurrence rateAcademic medical centreCase seriesImmunohistochemical featuresPrognostic aspectsClinicopathological analysisFemale ratioFollow-upColorectal cancer
2024
Endovascular arterial embolization versus conservative management with nasal packing alone for severe epistaxis: a nationwide cohort study
Chen H, Khunte M, Colasurdo M, Gunawardane S, Malhotra A, Gandhi D. Endovascular arterial embolization versus conservative management with nasal packing alone for severe epistaxis: a nationwide cohort study. Journal Of NeuroInterventional Surgery 2024, jnis-2024-022790. PMID: 39715667, DOI: 10.1136/jnis-2024-022790.Peer-Reviewed Original ResearchEndovascular arterial embolizationNasal packingSevere epistaxisPropensity score matchingNationwide Readmissions DatabaseArtery embolizationIschemic strokeCohort studyRates of patient morbidityHemorrhage risk factorsConservative management groupConservative managementRetrospective cohort studyNationwide cohort studyRate of ischemic strokeBalance patient characteristicsContemporary real-world dataAssociated with lower ratesPatients admitted to hospitalNon-routine dischargeRisk of ischemic strokeRecurrent epistaxisRecurrence ratePatient morbidityPatient characteristicsRecurrence patterns and evolution of submicroscopic and asymptomatic Plasmodium vivax infections in malaria-endemic areas of the Peruvian Amazon
Castillo S, Alvarez C, Rosas-Aguirre Á, Acosta C, Corder R, Gómez J, Guzmán M, Speybroeck N, Llanos-Cuentas A, Castro M, Rosanas-Urgell A, Ferreira M, Vinetz J, Gamboa D, Torres K. Recurrence patterns and evolution of submicroscopic and asymptomatic Plasmodium vivax infections in malaria-endemic areas of the Peruvian Amazon. PLOS Neglected Tropical Diseases 2024, 18: e0012566. PMID: 39480785, PMCID: PMC11527163, DOI: 10.1371/journal.pntd.0012566.Peer-Reviewed Original ResearchConceptsRisk of P. vivax infectionPlasmodium vivax malaria transmissionFactors associated with recurrenceVivax malaria transmissionPlasmodium vivax infectionMalaria-endemic areasPopulation-based cohort studyFrequency of recurrenceApplication of molecular diagnostic methodsMalaria recurrenceMalaria infectionMalaria transmissionVivax infectionRecurrence rateMolecular diagnostic methodsRecurrence riskConsequences of prolonged exposureFollow-upCohort studyEndemic settingsRecurrenceAsymptomatic infectionAsymptomatic casesInfectionInitial infectionOutcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis
Al Kasab S, Almallouhi E, Shu L, Kicielinski K, Salehi Omran S, Liebeskind D, Zubair A, Vedovati M, Paciaroni M, Antonenko K, Heldner M, de Havenon A, Henninger N, Yaghi S. Outcomes and Recurrence Rates Among Patients With Provoked and Cryptogenic Cerebral Venous Thrombosis. Neurology Clinical Practice 2024, 15: e200381. PMID: 39399562, PMCID: PMC11464219, DOI: 10.1212/cpj.0000000000200381.Peer-Reviewed Original ResearchRisk of recurrent venous thromboembolismRecurrent venous thromboembolismCerebral venous thrombosisVenous thromboembolismFemale patientsVenous thrombosisBaseline characteristicsOutcome of cerebral venous thrombosisRate of recurrent venous thromboembolismProvoking factorsRare cause of strokeTransient provoking factorsKaplan-Meier survival analysisDuration of anticoagulationOutcomes of patientsMann-Whitney <i>Cause of strokeConsecutive patientsRare causeRecurrence rateMale patientsMulticenter studyRetrospective databaseStandard treatmentCox regressionThe 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile
Boustany A, Feuerstadt P, Tillotson G. The 3 Ds: Depression, Dysbiosis, and Clostridiodes difficile. Advances In Therapy 2024, 41: 3982-3995. PMID: 39276186, PMCID: PMC11480130, DOI: 10.1007/s12325-024-02972-0.Peer-Reviewed Original ResearchIncreased risk of C. difficile infectionRisk of C. difficile infectionClasses of antidepressantsClostridioides difficile infectionNovel treatment optionsPatients' quality of lifeMicrobiome-related factorsDevelopment of dysbiosisOpportunistic infectionsRecurrent CDIGut microbiomeRecurrence rateAntidepressant useDifficile infectionMental disordersTreatment optionsLive biotherapeutic productsComplex pathophysiologyIncreased riskC. difficileGut dysbiosisQuality of lifePatients' qualitySignificant healthcare concernAntidepressantsPrimary Treatment of Eyelid Conjunctival Melanoma with Immunotherapy: A Case Report
Weiss M, Perzia B, Sinard J, Tran T, Maeng M. Primary Treatment of Eyelid Conjunctival Melanoma with Immunotherapy: A Case Report. Ophthalmic Plastic And Reconstructive Surgery 2024, 41: e12-e15. PMID: 39240220, DOI: 10.1097/iop.0000000000002776.Peer-Reviewed Original ResearchConjunctival melanomaImmune checkpoint inhibitor regimenCombination of ipilimumabFirst-line combinationImmune checkpoint inhibitorsMonths of treatmentSystemic adverse effectsCutaneous melanoma treatmentHigher recurrence rateCheckpoint inhibitorsMucosal melanomaAdjuvant therapyDisease resolutionRecurrence rateLocal surgeryMelanoma treatmentFrequent metastasisCase reportPrimary treatmentMelanomaClinical approachIpilimumabNivolumabConjunctivalAdverse effectsPatients with ulcerative colitis who have normalized histology are clinically stable after de-escalation of therapy
Akiyama S, St-Pierre J, Traboulsi C, Silfen A, Rai V, Rodriguez T, Erondu A, Steinberg J, Shaffer S, Christensen B, Rubin D. Patients with ulcerative colitis who have normalized histology are clinically stable after de-escalation of therapy. Npj Gut And Liver 2024, 1: 5. DOI: 10.1038/s44355-024-00005-9.Peer-Reviewed Original ResearchHistologic normalizationUlcerative colitisDe-escalationUC patientsDe-escalation of therapyTherapeutic de-escalationMedian follow-upDe-escalation groupProportion of patientsStudy assessed outcomesHistological recurrenceRecurrence rateSingle-centerClinical stabilityTherapeutic changeRemission outcomesFollow-upTherapyPatientsImmunomodulationAminosalicylatesWithdrawalColitisMonthsOutcomesProteogenomic characterization of pancreatic neuroendocrine tumors uncovers hypoxia and immune signatures in clinically aggressive subtypes
Tanaka A, Ogawa M, Zhou Y, Otani Y, Hendrickson R, Miele M, Li Z, Klimstra D, Wang J, Roehrl M. Proteogenomic characterization of pancreatic neuroendocrine tumors uncovers hypoxia and immune signatures in clinically aggressive subtypes. IScience 2024, 27: 110544. PMID: 39206147, PMCID: PMC11350455, DOI: 10.1016/j.isci.2024.110544.Peer-Reviewed Original ResearchClinically aggressive subtypePancreatic neuroendocrine tumorsProteomic subtypesNeuroendocrine tumorsAggressive subtypeImmune hot tumorsSystemic treatment optionsVariable clinical outcomesTumor grading systemPredicting patient outcomesHot tumorsCytotoxic chemotherapyImmune signaturesImmunosuppressive moleculesImmunotherapy targetClinical aggressivenessSomatostatin analogsRecurrence rateClinical outcomesTreatment optionsEndocrine neoplasmsGlycolysis upregulationPanNETsProteogenomic characterizationInflammatory pathwaysFamilial Recurrence of Autism: Updates From the Baby Siblings Research Consortium.
Ozonoff S, Young G, Bradshaw J, Charman T, Chawarska K, Iverson J, Klaiman C, Landa R, McDonald N, Messinger D, Schmidt R, Wilkinson C, Zwaigenbaum L. Familial Recurrence of Autism: Updates From the Baby Siblings Research Consortium. Pediatrics 2024, 154 PMID: 39011552, PMCID: PMC11291960, DOI: 10.1542/peds.2023-065297.Peer-Reviewed Original ResearchRecurrence rateFamilial recurrence rateDatabase of infantsMale infant sexPredictors of recurrenceAssociated with recurrencePopulation-based studyMultiple affected siblingsProspective studyInfant sexHierarchical generalized linear modelsDiagnostic evaluationFamilial recurrenceAutism spectrum disorderRecurrenceResearch ConsortiumFemale probandsMultinational databaseMale probandsMaternal educationProbandsFemale siblingsProband sexLikelihood ratioCalculate likelihood ratiosAdvances in chronic subdural hematoma and membrane imaging
Chen H, Colasurdo M, Malhotra A, Gandhi D, Bodanapally U. Advances in chronic subdural hematoma and membrane imaging. Frontiers In Neurology 2024, 15: 1366238. PMID: 38725642, PMCID: PMC11079242, DOI: 10.3389/fneur.2024.1366238.Peer-Reviewed Educational MaterialsChronic subdural hematomaMiddle meningeal artery embolizationSubdural hematomaDeterminants of disease recurrenceChronic subdural hematoma recurrenceDual-energy CT imagingChronic subdural hematoma membranesDisease recurrenceArtery embolizationEmbolization treatmentRecurrence rateSurgical managementRadiographic biomarkersSurgical planningHematomaCT imagesRecurrenceNeurosurgical diseasesEmbolizationNarrative reviewTreatmentHeterozygous CDKN2A Loss is Associated with Recurrence and Survival in High, But Not Low Grade Meningiomas
Tabor J, O'Brien J, Valero S, Pappajohn A, McGuone D, Erson-Omay Z, Yasuno K, Gunel M, Moliterno J. Heterozygous CDKN2A Loss is Associated with Recurrence and Survival in High, But Not Low Grade Meningiomas. Neurosurgery 2024, 70: 203-203. DOI: 10.1227/neu.0000000000002810_112.Peer-Reviewed Original ResearchProgression-free survivalHigh-grade meningiomasOverall survivalNF2 mutationsDecreased PFSLow grade meningiomasWHO grading criteriaLow-grade meningiomasAssociated with recurrenceSomatic NF2 mutationsHigher recurrence rateSomatic driver mutationsAggressive clinical characteristicsIncreased chromosomal instabilityLoss of CDKN2A/BHigh-copy number variationCDKN2A mutationsCopy number variationsAggressive meningiomasLow-grade onesProliferative indexCDKN2A lossGrade meningiomasRecurrence rateMitotic countPreclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer
McNamara B, Demirkiran C, Hartwich T, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz P, Coma S, Pachter J, Santin A. Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer. Gynecologic Oncology 2024, 183: 133-140. PMID: 38493021, DOI: 10.1016/j.ygyno.2024.01.028.Peer-Reviewed Original ResearchLow grade serous ovarian carcinomaWhole-exome-sequencingGain-of-function mutationsVS-4718Preclinical efficacyLow grade serous ovarian cancerSerous ovarian cancerControl-treated miceTumor growth inhibitionWild-type KRASLoss of heterozygosityDecreased p-ERKRAF/MEK inhibitionMedian survivalOvarian cancerRecurrence rateTherapeutic optionsOral gavageTumor growthTumor samplesIn vivo activityMAPK pathway genesRAF/MEK inhibitorsP-ERKEx vivo
2023
Utility of Repeat Uterine Cavity Evaluation in the Infertility Workup
Dolinko A, Danilack V, Alvero R, Snegovskikh V. Utility of Repeat Uterine Cavity Evaluation in the Infertility Workup. Journal Of Women's Health 2023, 33: 171-177. PMID: 38117546, PMCID: PMC10880290, DOI: 10.1089/jwh.2023.0302.Peer-Reviewed Original ResearchSaline infusion sonohysterographyUterine cavity evaluationUterine cavity abnormalitiesInfertility workupInitial imagingRisk factorsSingle academic medical centerAbnormal uterine cavityInitial imaging findingsPeak estradiol levelsRetrospective cohort studyLive birth rateBody mass indexAcademic medical centerEligible patientsPrior abnormalitiesUterine instrumentationCohort studyInfertile womenImaging findingsMass indexEstradiol levelsRecurrence rateImaging outcomesUterine cavityEPCO-47. HETEROZYGOUS CDKN2A LOSS IS ASSOCIATED WITH HIGHER RECURRENCE AND LOWER SURVIVAL IN HIGH-, BUT NOT LOW-GRADE MENINGIOMAS
Tabor J, Chavez M, O'Brien J, Morales-Valero S, Pappajohn A, McGuone D, Erson-Omay Z, Yasuno K, Gunel M, Moliterno J. EPCO-47. HETEROZYGOUS CDKN2A LOSS IS ASSOCIATED WITH HIGHER RECURRENCE AND LOWER SURVIVAL IN HIGH-, BUT NOT LOW-GRADE MENINGIOMAS. Neuro-Oncology 2023, 25: v134-v135. PMCID: PMC10639255, DOI: 10.1093/neuonc/noad179.0509.Peer-Reviewed Original ResearchProgression-free survivalShorter progression-free survivalHigh recurrence rateHigh-grade meningiomasCDKN2A/BOverall survivalRecurrence rateLow-grade meningiomasHeterozygous lossNF2 mutationsHigh mitotic countFree survivalMethods ClinicalSomatic NF2 mutationsClinical associationsLower OSHigh recurrenceLow-grade onesProliferative indexMitotic countAggressive meningiomasClinical implicationsMeningiomasPotential associationSkull baseAssociation of short-term hospital-level outcome metrics with 1-year mortality and recurrence for US Medicare beneficiaries with ischemic stroke
Wang Y, Leifheit E, Goldstein L, Lichtman J. Association of short-term hospital-level outcome metrics with 1-year mortality and recurrence for US Medicare beneficiaries with ischemic stroke. PLOS ONE 2023, 18: e0289790. PMID: 37561680, PMCID: PMC10414659, DOI: 10.1371/journal.pone.0289790.Peer-Reviewed Original ResearchConceptsIschemic strokeInverse probability weightsStroke patientsCause mortalityOutcome metricsLower riskUS hospitalsBetter long-term outcomesRecurrent stroke rateIschemic stroke recurrenceIschemic stroke patientsLong-term outcomesUS Medicare beneficiariesPerformance categoriesIntermediate hospitalsRecurrent strokeStroke recurrenceCohort studyClinical factorsRecurrence ratePrincipal diagnosisPatient riskStroke rateReadmission measuresCox modelSequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
Tan W, McElree I, Davaro F, Steinberg R, Bree K, Navai N, Dinney C, O'Donnell M, Li R, Kamat A, Packiam V. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. European Urology Oncology 2023, 6: 531-534. PMID: 37468392, DOI: 10.1016/j.euo.2023.06.011.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinIntermediate-risk non-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancerIntermediate-riskMulti-institutional retrospective reviewBlue light cystoscopyCombination of docetaxelEvaluate oncological outcomesHigh-grade diseaseMedian follow-upCancer-specific mortalityTreatment groupsCancer control outcomesBladder cancer groupSequential gemcitabineChemotherapy combinationsOncological outcomesIntravesical gemcitabinePostoperative chemotherapyAdjuvant treatmentRetrospective reviewRecurrence rateCancer groupThe genetic epidemiology of obsessive-compulsive disorder: a systematic review and meta-analysis
Blanco-Vieira T, Radua J, Marcelino L, Bloch M, Mataix-Cols D, do Rosário M. The genetic epidemiology of obsessive-compulsive disorder: a systematic review and meta-analysis. Translational Psychiatry 2023, 13: 230. PMID: 37380645, PMCID: PMC10307810, DOI: 10.1038/s41398-023-02433-2.Peer-Reviewed Original ResearchConceptsFirst-degree relativesSystematic reviewPopulation-based studyGenetic epidemiologyRelatives of childrenOutcomes of interestFirst systematic reviewObsessive-compulsive disorderRecurrence rateFamilial recurrence rateMedical recordsOpenGrey databasesControl groupControl probandsFamilial disorderAdolescent probandsStudy designEpidemiologyTwin study designOCD diagnosisIndependent researchersDizygotic twinsTwin pairsDisordersOCDBorderzone Infarcts and Recurrent Cerebrovascular Events in Symptomatic Intracranial Arterial Stenosis: A Systematic Review and Meta-Analysis
Das S, Shu L, Morgan R, Shah A, Fayad F, Goldstein E, Chahien D, Maglinger B, Bokka S, Owens C, Abbasi M, Kvernland A, Siegler J, Mac Grory B, Nguyen T, Furie K, Khatri P, Mistry E, Prabhakaran S, Liebeskind D, Romano J, de Havenon A, Palaiodimou L, Tsivgoulis G, Yaghi S. Borderzone Infarcts and Recurrent Cerebrovascular Events in Symptomatic Intracranial Arterial Stenosis: A Systematic Review and Meta-Analysis. Journal Of Stroke 2023, 25: 223-232. PMID: 37282372, PMCID: PMC10250880, DOI: 10.5853/jos.2023.00185.Peer-Reviewed Original ResearchBorderzone infarctsIntracranial arterial stenosisRisk ratioNeurological deteriorationSystematic reviewRecurrent strokeInfarct patternsArterial stenosisAnterior circulation stroke patientsSymptomatic intracranial arterial stenosisRecurrent cerebrovascular eventsPosterior circulation strokeSymptomatic ICACerebrovascular eventsStroke recurrenceTerritorial infarctsDistal perfusionRecurrence rateStroke patientsSubgroup analysisThrombus embolizationOutcome eventsPlaque progressionInclusion criteriaHigh riskSurgical strategies for intracranial meningioma in the molecular era
Dincer A, Morales-Valero S, Robert S, Tabor J, O’Brien J, Yalcin K, Fulbright R, Erson-Omay Z, Dunn I, Moliterno J. Surgical strategies for intracranial meningioma in the molecular era. Journal Of Neuro-Oncology 2023, 162: 253-265. PMID: 37010677, PMCID: PMC10167142, DOI: 10.1007/s11060-023-04272-z.Peer-Reviewed Original ResearchConceptsExtent of resectionGrade 1 tumorsInfluence of surgeryTreatment of choiceHigh recurrence rateBiology of meningiomasIntroductionSurgical resectionSymptomatic recurrenceDisease recurrenceDefinitive managementRecurrence rateSurgical strategyWHO gradeIntracranial meningiomasClinical predictive powerMalignant transformationGrading scaleNatural historyMeningiomasUnexpected recurrenceRecurrence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply